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Abstract
Purpose—Asian-American men with prostate cancer have been reported to present with higher
grade and later stage disease than White Americans. However, Asian Americans comprise a
heterogeneous population with distinct health outcomes. We compared prostate cancer risk
profiles among the diverse racial and ethnic groups in California.
Materials and Methods—We used data from the California Cancer Registry for 90,845 Non-
Hispanic White, Non-Hispanic Black, and Asian-American men diagnosed with prostate cancer
between 2004 and 2010. Patients were categorized into low, intermediate, or high-risk groups
based on clinical stage, Gleason score, and PSA value at diagnosis. Using polytomous logistic
regression, we estimated adjusted odds ratios for the association of race/ethnicity and nativity with
risk group.
Results—In addition to Non-Hispanic Blacks, six Asian-American groups (US-born Chinese,
foreign-born Chinese, US-born Japanese, foreign-born Japanese, foreign-born Filipino, and
foreign-born Vietnamese) were more likely to have an unfavorable risk profile compared to Non-
Hispanic Whites. The odds ratios for high vs. intermediate-risk disease ranged from 1.23 (95% CI,
1.02–1.49) for US-born Japanese to 1.45 (95% CI, 1.31–1.60) for foreign-born Filipinos. These
associations appeared to be driven by higher grade and PSA values, rather than advanced clinical
stage at diagnosis.
Conclusions—In this large, ethnically diverse population-based cohort, we found that Asian-
American men were more likely to have unfavorable risk profiles at diagnosis. This association
varied by racial/ethnic group and nativity, and was not attributable to later stage at diagnosis,
suggesting that Asian men may have biological differences that predispose to the development of
more severe disease.
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In men with prostate cancer (PCa), it is clinically important to distinguish between low risk
disease, where treatment-related morbidity could be minimized through active surveillance,
and high-risk disease, where more aggressive treatment may be indicated. Risk stratification
tools based on prognostic factors such as Gleason score (GS), serum prostate specific
antigen (PSA), and stage are widely used to categorize men into pretreatment risk groups
that predict disease progression1, 2.
PCa clinical characteristics vary by race/ethnicity3–6 and birthplace7, 8. Studies have
suggested that Asian-Americans have proportionally more advanced stage9–11 and high
grade9, 10, 12–14 disease compared to Whites, which could have significant implications for
treatment and prognosis in this population. However, previous studies were unable to
disaggregate Asian subpopulations by ethnicity and birthplace, or were based upon data
collected prior to the widespread adoption of PSA screening or in selected clinical
populations.
Using a pretreatment risk stratification approach, we compared clinical risk profiles among
Asian-American populations, defined by ethnicity and birthplace, to those of Non-Hispanic
(NH) Whites and NH Blacks in a large population-based cohort.
PATIENTS AND METHODS
The California Cancer Registry (CCR) comprises four registries from the NCI’s
Surveillance, Epidemiology and End Results (SEER) program. We used tumor and
demographic data collected through the CCR for men diagnosed with adenocarcinoma of the
prostate during the years 2004–2010. These years were selected because GS and PSA were
unavailable prior to 2004. We limited our study to men with first primary tumors, not
diagnosed solely on death certificate or autopsy, and further restricted to NH Whites, NH
Blacks, or members of one of the six largest Asian racial/ethnic groups in California:
Chinese, Japanese, Filipino, Korean, Vietnamese, and South Asian (n=102,824). Using a
previously described validated algorithm based on age at issue of social security number15,
we imputed nativity for the 38% of Asian-American men whose place of birth was unknown
in the registry data. US born Koreans (n=13), Vietnamese (n=19), and South Asians (n=61)
were excluded because of small numbers that limited meaningful analyses. We further
excluded cases with clinical stage T0 (n=23) or unknown (n=2510), unknown GS (n=2806),
or unknown PSA value (n=6547). The final cohort consisted of 90,845 men.
Cases were geocoded to their census block group of residence at the time of diagnosis.
Using a previously described composite measure of neighborhood socioeconomic status
(SES) based on block group at diagnosis16, we assigned men to an SES quintile based on the
statewide distribution.
Using a modification of the original D’Amico risk groups17, we categorized men into three
clinical risk groups. Men with a highest pre-treatment PSA > 20 ng/ml, GS ≥ 8, or stage cT3
or higher were classified as having high-risk disease (n=19,648). Men with stage cT1-cT2a,
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PSA ≤ 10 ng/ml, and GS ≤ 6 were classified as having low-risk disease (n=26,918). The
remainder were considered to have intermediate-risk disease (n=44,279).
Statistical Analyses
Differences in distributions of disease and sociodemographic characteristics among groups
were compared using chi-square tests. Medians were compared using the Kruskal-Wallis
test. Comparisons to NH Whites were performed for each racial/ethnic group and p-values
were adjusted for multiple comparisons using the step-down Bonferroni method18 as
implemented in the SAS MULTTEST procedure.
Because high and low risk disease carry well-defined, but distinctly different, treatment
recommendations, we used polytomous logistic regression to estimate adjusted odds ratios
(ORs) and 95% confidence intervals (CIs) for the association of race/ethnicity with these
risk categories compared to intermediate risk. To further analyze the nature of this
relationship, we deconstructed the overall risk category and modeled the association of race/
ethnicity with each component prognostic factor using polytomous logistic regression. Each
factor was categorized into high, intermediate, and low-risk categories using the same
cutpoints that were used to define overall risk groups.
Statistical analyses were performed with SAS 9.3 (SAS Institute, Cary, NC).
This study was approved by the Institutional Review Board of the Cancer Prevention
Institute of California.
RESULTS
The sociodemographic and clinical characteristics of the cohort are described in Table 1.
Median age at diagnosis was older for foreign-born (FB) Chinese, FB Japanese, FB
Filipinos, FB Koreans, FB Vietnamese, and US-born (USB) Japanese, and younger for USB
Filipinos and NH Blacks compared to NH Whites. The majority of the Asian groups (FB
Chinese, USB Japanese, FB Japanese, FB Filipino, FB Korean, and FB Vietnamese) had
higher proportions of men with high GS, and all groups except USB Chinese and USB
Filipinos had lower proportions of men with low PSA compared to NH Whites. The
proportion of patients diagnosed with high-risk disease was higher among FB Chinese, USB
and FB Japanese, FB Filipinos, FB Vietnamese, and NH Blacks compared to NH Whites.
Interestingly, several groups (NH Black, USB Chinese and FB Chinese) presented with
favorable clinical stage distribution relative to NH Whites.
The odds of presenting with an adverse risk profile compared unfavorably to NH Whites for
the majority of the racial/ethnic groups, after adjusting for age, SES, marital status, and year
of diagnosis (Table 2). The effect sizes observed in the Asian groups were similar to those in
NH Blacks. However, the pattern of prognostic factors conferring this increased risk differed
among the groups (Table 3).
USB Chinese were more likely than NH Whites to be diagnosed with high vs. intermediate-
risk disease (OR, 1.34; 95% CI, 1.05–1.71). This resulted from higher odds of high vs.
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intermediate GS (OR, 1.58; 95% CI, 1.19–2.11), and lower odds of low vs. intermediate
PSA category (OR, 0.76; 95% CI, 0.58–0.98) compared to NH Whites. FB Chinese had a
similar profile as their US-born counterparts, with increased odds of high vs. intermediate-
risk disease relative to NH Whites (OR 1.35; 95% CI, 1.20–1.52), apparently also
attributable to an increased likelihood of high vs. intermediate GS (OR, 1.36; 95% CI, 1.18–
1.57) and decreased likelihood of low vs. intermediate PSA (OR, 0.67; 95% CI, 0.59–0.76).
Interestingly, USB and FB Chinese were more likely than NH Whites to be diagnosed with
early vs. intermediate stage (OR, 1.52; 95% CI 1.19–1.93 and OR, 1.46; 95% CI, 1.29–1.64,
respectively) but not advanced stage disease.
USB Japanese were more likely to have high-risk (OR, 1.23; 95% CI 1.02–1.49) and less
likely to have low-risk disease (OR, 0.74; 95%CI 0.60–0.92) vs. intermediate-risk disease
compared to NH Whites. The unfavorable risk profile in USB Japanese was attributable to
decreased odds of low vs. intermediate PSA levels at diagnosis (OR, 0.79; 95% CI 0.64–
0.97). FB Japanese also had a decreased likelihood of low vs. intermediate-risk disease (OR,
0.61; 95% CI 0.42–0.90), but their likelihood of high vs. intermediate-risk disease did not
differ from NH White men. In addition to decreased odds of low vs. intermediate PSA levels
(OR, 0.59; 95% CI, 0.42–0.84), they also had decreased odds of low vs. intermediate GS
(OR, 0.67; 95% CI 0.48–0.93) at diagnosis.
While USB Filipinos did not differ from NH Whites in any risk categories, FB Filipino men
had the highest odds of being diagnosed with high vs. intermediate-risk disease of any group
(OR, 1.45; 95% CI, 1.31–1.60). FB Filipinos were more likely to have high vs. intermediate
GS (OR, 1.27; 95% CI, 1.12–1.43), high vs. intermediate PSA (OR, 1.35; 95% CI, 1.17–
1.56), and less likely to have low vs. intermediate PSA (OR, 0.72; 95% CI, 0.65–0.81).
However, like Chinese men, they were more likely to be diagnosed at an early vs.
intermediate stage (OR, 1.18; 95% CI, 1.07–1.30).
Compared to NH Whites, FB Vietnamese had higher odds of high vs. intermediate-risk
disease (OR, 1.39; 95% CI, 1.13–1.72), resulting from higher odds of high vs. intermediate
GS (1.37; 95% CI, 1.05–1.77) and lower odds of low vs. intermediate PSA (OR, 0.59; 95%
CI, 0.48–0.74). They also had a higher likelihood of being diagnosed at an early vs.
intermediate stage (OR, 1.39; 95% CI, 1.13–1.71).
FB South Asians and FB Koreans did not differ from NH Whites in overall risk category,
but compared unfavorably to NH Whites for at least one prognostic factor.
Older age, lower SES, lack of health insurance at diagnosis, and unmarried and unknown
marital status were associated with increased odds of high vs. intermediate-risk disease.
Similarly, older age, lack of health insurance, and the lowest vs. highest SES quintile were
associated with decreased odds of having low vs. intermediate-risk disease.
To assess the effect of excluding men with incomplete prognostic factor data, we performed
a sensitivity analysis, imputing risk group. Men who had at least one prognostic factor in the
high category were assigned to the high-risk group, and men with two known prognostic
factors were assigned to the highest of the two known categories. Using this method, we
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were able to assign a risk category to 98% of our cases. The results using imputed risk
category were similar to the complete case analysis (Supplementary Table 1).
DISCUSSION
To our knowledge, no prior studies have examined proportional differences in PCa clinical
characteristics jointly by birthplace and specific Asian ethnicity. In a large, multiethnic
population-based study we found six specific Asian-American groups were more likely to
have unfavorable clinical risk profiles than NH Whites. With the exception of USB
Filipinos, all Asian groups were more likely to have at least one unfavorable prognostic
factor at diagnosis. These findings have important clinical implications as categorization
into a higher risk stratum limits treatment choices and predicts disease progression.
The unfavorable risk profile seen in many of the Asian-American groups could partly be
explained by differences in screening behavior. Asian-Americans report less PSA screening
than NH White men in California19. In our study, all Asian-American groups except USB
Filipinos were less likely than NH Whites to have low PSA at diagnosis. In the National
Cancer Database, Asian and Pacific Islander race/ethnicity was also associated with higher
PSA at diagnosis14, whereas this association was not observed in a military-insured
population with mandatory PSA screening13, supporting the notion that elevated PSA at
diagnosis may be related to screening behavior.
Earlier studies using pre- and early-PSA era data found that, consistent with decreased
screening behavior, Asian-Americans were more likely than NH Whites to be diagnosed at a
more advanced stage9–11. However, neither we nor Fedewa et al.14 found such an
association using contemporary data. Instead, we found that FB Chinese, FB Vietnamese,
FB Filipinos, and USB Chinese were more likely to present with early stage disease, similar
to findings in a population with mandatory PSA screening13.
The association of Asian-American race/ethnicity with high GS that we and others
observed9, 10, 12–14 is also not likely to be explained by screening behavior, as higher GS has
not clearly been linked to the timing of diagnosis20. Furthermore, in populations with low
screening penetrance, Zlotta et al. found that while Japanese and Caucasian men had similar
prevalence of latent PCa at autopsy, Japanese men were more likely to harbor high grade
disease12.
While differences in screening behavior may account for higher PSA at diagnosis, the
association with high grade and the lack of association with advanced stage at diagnosis
suggests that the differences we observed in risk profile cannot fully be explained by
screening behaviors or delayed access to care, and may be attributable to an underlying
intrinsic biological mechanism.
Androgens play an important role in prostatic carcinogenesis, and racial differences in
androgen metabolism have been documented21. Studies have noted that Asians have lower
5α-reductase activity21–23, and an association between reduced 5α-reductase activity and
high grade is supported by evidence from the Prostate Cancer Prevention Trial (PCPT) and
Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial, where an increased
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risk of high grade cancers was observed despite a reduction in the overall incidence of PCa
in men taking 5α-reductase inhibitors24, 25. It has been hypothesized that the low
intraprostatic androgen levels resulting from 5α-reductase inhibition may selectively inhibit
low grade cancers and favor the selection of poorly differentiated cancer cells resulting in
higher grade tumors. Alternatively, reduction in prostate size from decreased 5α-reductase
activity may facilitate increased detection of high grade disease on biopsy25. Whether
through preferential selection or increased detection of higher grade tumors, lower 5α-
reductase activity may be one factor contributing to the increased likelihood of
categorization of Asian PCa patients into higher clinical risk categories.
In our study, birthplace was associated with a strikingly different risk profile in Filipino men
but less so in Chinese and Japanese men, which may reflect differences in acculturation,
environmental exposures, or lifestyle factors among these groups. Our findings reinforce the
importance of considering both detailed ethnicity and nativity when studying cancer
outcomes among the heterogeneous Asian-American population15.
While our findings are provocative, a greater understanding of the outcomes of high risk
prostate cancer in Asian men is necessary before screening and treatment practices are
changed. Some studies have found that Asian-American men, despite their poorer prognostic
features at diagnosis, have better survival and biochemical recurrence outcomes than NH
White men9, 10, 13, suggesting that the traditional criteria used to determine clinical risk may
be inadequate to assess the risk of disease progression in Asian populations.
Like all observational, registry-based studies, this study has some limitations. Our results
may be affected by potential misclassification of race/ethnicity and/or nativity. While
registry data on birthplace has been shown to be highly accurate at the level of US or foreign
birth26, there may be some misclassification associated with our imputation method. Further,
misclassification of specific Asian race/ethnicity27 may have biased the results toward the
null, as the extent of misclassification is most likely non-differential with regard to the
outcomes of interest. Another limitation is that data on tumor volume, and the number and
involvement of biopsy cores were not available. However, the available data were sufficient
to stratify men into the broad recurrence risk groups that guide the initial management
choices in the National Comprehensive Cancer Network guidelines28. Finally, we were
unable to control for prostate size or body mass index, which may be associated with
grade13, 25, 29.
Our study has several strengths. California is home to the largest and most diverse Asian-
American population in the United States, accounting for approximately one third of all U.S.
Asian-Americans30. We therefore had sufficient numbers to be able to disaggregate the
Asian-American population by ethnicity and birthplace, and were able to demonstrate the
heterogeneity that exists among these groups. By using data from a state-mandated registry
that captures all cancer cases in California, the results are less susceptible to reporting and
selection bias than studies that rely on voluntary reporting or specific health care systems
and patient populations, and are widely applicable to the general population.
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Given the indolent nature of the majority of prostate cancers currently being diagnosed,
determining the risk of disease progression is important in guiding treatment decisions. We
found that most Asian-American groups present with higher risk disease than NH Whites.
Further research is necessary to assess whether the poorer risk profiles we observed in this
study translate to worse clinical outcomes in these Asian-American populations.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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